



Attorney Docket No. PC11088A
Application No. 09/995,130

1617

I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Hon. Commissioner for Patents, Washington, D.C. 20231 on this 4th day of April 2003.

By

Mary C Bickel

(Signature of person mailing)

Mary C. Bickel

(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): David B. MacLean, et al.

Examiner: Mojdeh Bahar

Application No.: 09/995,130

Art Unit: 1617

Filing Date: 11/27/2001

Title: THERAPY FOR ANDROPAUSE USING ESTROGEN AGONISTS/ANTAGONISTS AND TESTOSTERONE

Box Non-Fee Amendment
Commissioner for Patents
Washington, D.C. 20231

Sir:

RESPONSE

This is a response to the Official Action dated March 25, 2003, which contained only restriction and election of species requirements.

Remarks

Applicants have been required to elect a group of claims for prosecution from groups I-XII. Applicants hereby elect the claims of Group I, claims 1-10 and 31-45. Applicants have also been required to elect a species relating to a medical condition and a chemical species. Applicants hereby elect the medical condition andropause. In addition, applicants elect the chemical species disclosed in claim 4, which is (-)-cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalenen-2-ol. The claims that read on the elected chemical species and the elected medical condition are claims 1-5.

Applicants believe that this application is in condition for allowance. Reconsideration and allowance is respectfully requested.

Date:

4/4/2003

By:

Todd M. Crissey

Todd M. Crissey
Registration No. 37,807
Pfizer Inc
Patent Department,
Box 8260-1611
Eastern Point Road
Groton, CT 06340
Phone: (860) 715-4331
Fax: (860) 441-5221

TECH CENTER 1600/2900

APR 10 2003

RECEIVED